Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608085 | 0.89 | SYK (0.44) | PRKCQGRIN2BSYKBCDIN3DJAK3 | |
| SCHEMBL3854340 | 0.87 | PRKCQ (0.55) | PRKCQ | |
| SCHEMBL3847762 | 0.83 | GRIN2B (0.45) | GRIN2BVNN1 | |
| SCHEMBL3852089 | 0.79 | PRKCQ (0.42) | PRKCQGRIN2BVNN1JAK3BTK | |
| SCHEMBL3848020 | 0.79 | USP1 (0.37) | GRIN2BVNN1JAK3 | |
| SCHEMBL13608083 | 0.77 | PRKCQ (0.51) | PRKCQ | |
| SCHEMBL19665574 | 0.76 | MAPK8 (0.40) | PRKCQGRIN2BSYKBCDIN3DJAK3 | |
| SCHEMBL3849773 | 0.75 | PRKCQ (0.41) | PRKCQ | |
| SCHEMBL13608070 | 0.74 | IRAK1 (0.43) | GRIN2BSYKBCDIN3DJAK3 | |
| SCHEMBL3851085 | 0.70 | PRKCQ (0.39) | PRKCQGRIN2BSYKBCDIN3DBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009062059-A2 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | PRKCQ 3/4885GRIN2B 953/4885VNN1 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.